The alterome, defined as all disease-driving genetic alterations, remains largely unaddressed by current therapies. While targeted therapies have brought meaningful progress to patients, many aggressive cancers lack effective treatment options. Available therapies often cause debilitating side effects due to off-target activity, which limits dosing and reduces their potential benefit. In addition, few options address genomically defined drivers. We’re working to change that by developing potentially safer, more precise therapies that aim to help patients stay on treatment longer, improve control of their cancer, and live better lives.
Independently, we bring varied backgrounds with diverse expertise. Collectively, we are dedicated to relentlessly pushing the boundaries of cancer treatments to transform the lives of those living with cancer.
